Compare Brookfield Infrastructure Partners LP (BIP) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brookfield Infrastructure Partners LP vs BioNano Genomics Inc — how do they compare? Brookfield Infrastructure Partners LP trades at $40.06 (market cap $18.10B), while BioNano Genomics Inc trades at $1.17 (market cap $13.66M). The key difference: Brookfield Infrastructure Partners LP is far larger — about 1325× BioNano Genomics Inc's market cap, and Brookfield Infrastructure Partners LP pays a 4.62% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BIP | BNGO | |
|---|---|---|
Market Cap | $18.10B | $13.66M |
Sector | Industrials | Health |
52-Week High | $42.62 | $4.92 |
52-Week Low | $29.81 | $1.06 |
Enterprise Value | $77.05B | $16.26M |
Dividend Yield | 4.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brookfield Infrastructure Partners (BIP) trades at $39.97, up 5.24% over 24 hours, with a bullish technical signal from moving averages. The stock shows strong analyst support with 13 buy ratings and a consensus price target of $44.67. Recent financials indicate revenue growth to $25.1 billion in 2026, though net income declined to $652 million. The company maintains a dividend yield with recent payouts of $0.46 per share and is undergoing corporate simplification to enhance shareholder value.
BIP presents a mixed outlook; attractive valuation metrics like EV/EBITDA of 6.97 and P/S of 0.72 suggest upside, but consecutive earnings misses and declining profitability margins pose risks. Investors may benefit from infrastructure demand and high dividend yields, yet should monitor execution on earnings targets and debt levels, with institutional sentiment leaning bullish amid macroeconomic uncertainties.
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
